Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

被引：0
|
作者：
Hosomi, Yukio
Yoh, Kiyotaka
Kasahara, Kazuo
Yamada, Kazuhiko
Takahashi, Toshiaki
Tanaka, Kaoru
Hida, Toyoaki
Yoshioka, Hiroshige
Kato, Terufumi
Takeda, Koji
Nishio, Makoto
Sakai, Hiroshi
Maemondo, Makoto
Takenoyama, Mitsuhiro
Nokihara, Hiroshi
Tatsumi, Masumi
Nakamura, Takashi
Enatsu, Sotaro
Tamura, Tomohide
Nakagawa, Kazuhiko
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Kanazawa Univ, Grad Sch Med Sci, Dept Resp Med, Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan
[4] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan
[5] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[6] Kiniki Univ, Fac Med, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[9] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan
[10] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Miyagi Canc Ctr, Sendai, Miyagi, Japan
[14] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan
[15] Natl Canc Ctr, Tokyo, Japan
[16] Eli Lilly Japan, Kobe, Hyogo, Japan
[17] Lilly Res Labs Japan, Kobe, Hyogo, Japan
[18] St Lukes Int Hosp, Tokyo, Japan
[19] Kinki Univ, Fac Med, Osakasayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
    Paz-Ares, Luis G.
    Perol, Maurice
    Ciuleanu, Tudor-Eliade
    Kowalyszyn, Ruben Dario
    Reck, Martin
    Lewanski, Conrad R.
    Syrigos, Konstantinos
    Arrieta, Oscar
    Prabhash, Kumar
    Park, Keunchil
    Pikiel, Joanna
    Goksel, Tuncay
    Lee, Pablo
    Zimmermann, Anna
    Carter, Gebra Cuyun
    Alexandris, Ekaterine
    Garon, Edward B.
    LUNG CANCER, 2017, 112 : 126 - 133
  • [22] A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer
    Choueiri, T. K.
    Vaishampayan, U. N.
    Yu, E. Y.
    Quinn, D. I.
    Hahn, N. M.
    Hutson, T. E.
    Ross, R. W.
    Rosenberg, J. E.
    Jacobus, S. J.
    Kantoff, P. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [23] Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).
    Smit, Egbert F.
    Perol, Maurice
    Reck, Martin
    Cappuzzo, Federico
    Bidoli, Paolo
    Cohen, Roger B.
    Gao, Ling
    Ernest, C. Steven
    Lee, Pablo
    Zimmermann, Annamaria
    Ferry, David
    Treat, Joseph
    Melemed, Allen S.
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Apatinib plus docetaxel as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) (NCT02780778)
    Pan, Z.
    Wang, C.
    Xie, G.
    Liu, D.
    Yan, Z.
    Li, Y.
    Jiang, Z.
    Wang, B.
    Li, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [27] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [28] A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
    Yoh, Kiyotaka
    Hosomi, Yukio
    Kasahara, Kazuo
    Yamada, Kazuhiko
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Koue, Toshiko
    Nakamura, Takashi
    Enatsu, Sotaro
    Lee, Pablo
    Ferry, David
    Tamura, Tomohide
    Nakagawa, Kazuhiko
    LUNG CANCER, 2016, 99 : 186 - 193
  • [29] Cisplatin plus docetaxel as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)
    Doria, Simona
    Prochilo, Tiziana
    Cafferata, Mara Argenide
    Tiseo, Marcello
    Ardizzoni, Andrea
    Baldini, Editta
    ANNALS OF ONCOLOGY, 2007, 18 : 28 - 29
  • [30] IMPACT OF KRAS CODON SUB-TYPES IN A PHASE II SECOND-LINE TRIAL IN KRAS-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) OF SELUMETINIB PLUS DOCETAXEL VERSUS DOCETAXEL ALONE
    Liptrot, Tom
    Mann, Helen
    Smith, Ian
    Mcwalter, Gael
    Dougherty, Brian
    Walker, Jill
    Orr, Maria C.
    Hodgson, Darren
    Shaw, Alice T.
    Pereira, Jose Rodrigues
    Jeannin, Gaelle
    Vansteenkiste, Johan
    Barrios, Carlos H. E.
    Franke, Fabio A.
    Crino, Lucio
    Jaenne, Pasi A.
    Smith, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S372 - S372
12345